Advancing DD01, a Ratio Optimized GLP-1/GCG Agonist for Rapid Liver Fat Reduction Regardless of Body Weight Loss & Exploring Novel Approaches for Oral Peptide Delivery

Time: 11:30 am
day: Conference Day One


  • Focusing on phase 1 clinical data of GLP-1/GCG treatment in obese/overweight patients with T2D and/or NASH
  • Understanding the significance of rapid liver fat reduction in NAFLD/NASH patients with GLP-1/GCG dual agonists
  • Introducing novel methods to orally deliver peptide drugs, improving ease of administration